Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on AKBA stock, giving a Buy rating on July 28.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Akebia Therapeutics’ strategic initiatives and potential for growth. The partnership with DaVita, a leading dialysis provider in the U.S., is a significant strategic move that addresses key barriers to the adoption of Akebia’s product, Vafseo. This collaboration is expected to enhance clinical evidence and facilitate the adoption of Vafseo across the dialysis industry, as DaVita’s influence could encourage other large dialysis organizations to follow suit.
Moreover, the VOCAL trial with DaVita is designed to tackle the challenges of “protocolization” that have been identified by key opinion leaders. The trial’s focus on a three-times-weekly dosing regimen and the examination of red-blood-cell quality improvements further strengthen Vafseo’s value proposition. These efforts demonstrate Akebia’s proactive approach to overcoming industry challenges and could serve as a catalyst for broader adoption, reinforcing the Buy rating.
Ruiz covers the Healthcare sector, focusing on stocks such as United Therapeutics, Amarin, and Aquestive Therapeutics. According to TipRanks, Ruiz has an average return of -7.1% and a 36.67% success rate on recommended stocks.
In another report released on July 28, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.